| BIONTECH SE SPON. ADRS 1 |
| USA |
| Gesundheit |
| US09075V1026 / A2PSR2 |
| 22UA (Frankfurt) / BNTX (NASDAQ) |
| FRA:22UA, ETR:22UA, 22UA:GR, NASDAQ:BNTX |
| - |
| https://biontech.de/ |
|
BioNTech SE is a biotechnology company focused on the development of immunotherapies and mRNA-based medicines for cancer and infectious diseases. The company’s current portfolio includes oncology programs such as personalized and off-the-shelf canc..
>Volltext.. |
| 20374.34 Mio. EUR |
| 6043.58 Mio. EUR |
| 2833.07 Mio. EUR |
| -333.12 Mio. EUR |
| -1257.34 Mio. EUR |
| -5.09 EUR |
| 302.74 Mio. EUR |
| 9937.29 Mio. EUR |
| 733.85 Mio. EUR |
| 8.29 |
| 10.01% |
| -78.26% |
| - |
| - |
| - |
| 02.06.22 - 1.8290012€ |
| - |
| BIONTECH |
| 03.08.26 |
|
||||
|
||||
|